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Introduction
Patients with clinically occult breast cancer with
nodal involvement account for almost 10-12% of
cases. With the increasing rates of mammography X-
rays and tumour screening programs, very small
tumours are early detected with lower rates of nodal
involvement. It has been demonstrated that axillary
dissection is indicated only in patients with nodal
involvement, in order to  decrease the rate of complica-
tions related to the procedure. 
Sentinel node biopsy relies on the issue that the first
node draining a body district will be involved in case of
invasive ductal carcinoma. If this node is histopatholo-
gically negative, then we can assume that the axilla is
free from metastasis. 
SUMMARY: Breast surgery and sentinel node biopsy. Our expe-
rience.
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Massive campaigns of screening of breast pathologies improved
early diagnosis of breast cancers. Most of these cancers are small- sized
(T1) and seldom show intraoperative nodal involvement. Sentinel
node biopsy is the elective choice in the abovementioned cases because,
if negative, it avoids axillary dissection. International literature reports
rates of false negative sentinel node biopsy ranging among 4,5 and
12%; results in our experience account for almost 6%.
As a consequence, there is the definite risk of potentially positive
axillas that will not be dissected with subsequent risk of axillary recur-
rence within 24 months. The reason of that could be related to the fact
that in Referral Centers this technique is performed in strictly selectio-
ned patients, so as to gain a diagnostic accuracy of 98%. The rate of
axillary recurrences does not justify the routinary axillary dissection,
since this is just a staging, not a therapeutic procedure. In case of
doubt, it can be recommended a close and careful  follow-up of the
axilla.
RIASSUNTO: Chirurgia della mammella e linfonodo sentinella.
Nostra esperienza.
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L’avvento delle campagne di screening per le malattie della mam-
mella ha incrementato la diagnosi precoce di carcinomi. La maggior
parte di questi ultimi sono di piccole dimensioni (T1) e verosimilmente
non presentano all’atto operatorio metastasi linfonodali. La biopsia del
linfonodo sentinella è divenuta metodica di elezione in tutti i casi
sopracitati poiché, in caso di negatività, evita la dissezione ascellare.
Non sempre questo obiettivo viene raggiunto; la letteratura internazio-
nale riporta quote di falsi negativi comprese tra il 4,5 ed il 12%; i
risultati della nostra esperienza si attestano intorno al 6%.
La conseguenza di percentuali così elevate si traduce nel mancato
trattamento di cavi ascellari potenzialmente positivi con il rischio di
recidiva ascellare entro 24 mesi. La causa va forse ricercata nel fatto
che  nei Centri d’Eccellenza questa metodica viene eseguita secondo
tutte le raccomandazioni dettate dalle Società Scientifiche e dalle Linee
Guida Internazionali così da avere una accuratezza diagnostica del
98%, mentre in altri Centri viene eseguita con i mezzi a disposizione
che non sempre permettono l’adempimento di tutte le raccomandazio-
ni sopracitate. La percentuale di incidenza di recidive ascellari non
giustifica comunque la dissezione ascellare di principio essendo
quest’ultimo un atto prettamente stadiativo e non terapeutico; nel
sospetto si può ricorrere ad un accurato follow up clinico e strumentale
dell’ascella.
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This procedure has been gaining acceptance from
10 years in order to ensure patients complete recovery,
avoiding axillary dissection. Nevertheless, yet this techni-
que is far from being perfect since it relies on the type of
marker used, site of injection, need for adequate structures
and skilled surgical staff. 
McMaster in 1988 edited a review from 11 reports
concerning sentinel node biopsy that showed a clear
identification of the sentinel node in 86% of cases
(range 6-98%). Among 1385 females the range was so
wide because of the kind of marker used. Also the rate
of false negatives was as high as 6,2% (range 4,7-
12,5%) after  immunoistochemistry. From then on
this values showed a remarkable decrease gaining up to
98% of diagnostic accuracy if performed according to
the recommendations suggested by Scientific Societies
and International Guidelines. 
Patients and methods
During 2003-2004 in our Unit of Breast Surgery 178 quadran-
tectomies with sentinel node biopsies in patients with stage T1
breast cancer and clinically negative axillary nodes were performed.
In all cases we performed the standard double procedure with sub-
dermal injection of labeled 99Tc albumin and vital colour Blue
Patent around the tumour 15-20 minutes before surgery.
The axilla was always detected by gamma-camera 30-45 minu-
tes after the injection and in 3 cases the sentinel node was detected
along the internal mammary chain. In these last two cases (carcino-
mas of the central gland), we performed sentinel node biopsy throu-
gh Chamberlain’s minimal anterior mediastinotomy with nodal
recruitment after division of the internal mammary veins; in one of
this two cases the biopsy led to minimal opening of the parietal pleu-
ra and subsequent drainage of the iatrogenic pneumothorax.
All the patients did not undergo previous breast surgery and
152 of them underwent stereotactic biopsy by Mammotome ten
days before. 
Results
Overall incidence of nodal involvement after senti-
nel node biopsy was 10% in our experience, which,
added to the 3 cases (2%) where no sentinel node at all
was found, raises to 11%. Therefore in 161 patients
with early ductal carcinoma we found a negative senti-
nel node. In 90% of cases it was a first level node (161),
in 8% (14) there were first and second level nodes (1)
and in three cases (2%) there was an internal mammary
node with no sentinel node along the interpectoral and
third level lymphatic chains; in 87% of cases we found
only one sentinel node. 
Only in 40% of positive sentinel nodes metastases
were detected introperatively; in the remaining 60%
we had to wait for the paraffin inclusion, full nodal sec-
tions and immunoistochemistry to confirm the presen-
ce of micrometastasis (in 5 of 9 nodes); this result led
us to perform a second-step axillary dissection.
Discussion
Nowadays breast cancers are early detected and
often not palpable; the wide diffusion of screening pro-
grams allowed an early diagnosis in most of patients
rather than ten years ago. As a result, breast conservati-
ve surgery has widely spread, mostly for what it con-
cerns the axilla..
We reviewed charts from our series because we
firmly believe that the prognosis of breast cancer is
strictly related to the tumour itself and the risk of axil-
lary metastases depends on the size and the growth of
the tumour. The low incidence of nodal metastases in
our patients in T1a-T1b stages led us to take into
account the opportunity to perform the sentinel node
biopsy in selected patients. Since 7 years several reports
in literature appeared supporting the hypothesis of
avoiding the treatment of the axilla in breast cancers. In
1997, Huffy et al. (2) edited data concerning their
series of 955 patients suffering from breast cancers with
a long-lasting follow-up: 565 among these patients
underwent axillary dissection; 360 did not receive any
axillary treatment at all. The data collected did not evi-
dence any suspect node at follow-up in patients who
did not receive axillary surgery but radiotherapy of the
internal mammary, upperclavear and axillary chains. 
The rate of locoregional or distant metastases, so as
overall survival, were overlappable among the two
groups. Soon after Fein  edited data concerning a series
of 1598 patients suffering from stage I and stage II car-
cinomas concluding that axillary dissection could be
avoided in all T1a tumours detected at mammography,
in T1b patients detected at mammography and in
patients aged less than 40 or in cases of tubular adeno-
carcinoma up to 1 cm of diameter.
In 2002 Fisher (4) edited data from a 25-year fol-
low-up of a randomized trial comparing modified radi-
cal mastectomy, simple mastectomy plus radiotherapy
or simple mastectomy without radiotherapy  and subse-
quent axillary dissection in case of axillary recurrence.
There was no difference among the three groups in
terms of disease-free survival, local and distant disease-
free survival and overall survival. The Author conclu-
ded that removing clinically occult positive nodes at
surgery does not add advantage at all.
Thus, based on the fact that negativity for hormone
receptors, high mitotic index, aneuploidy and c-erb2
overexpression condition a worse prognosis, even in
absence of nodal involvement, we can conclude that
for stage T1 breast cancers  an accurate histopathologic
and biomolecular anamnesis can replace the prognostic
value of the axillary dissection (5).
If we really believe in the staging role of axillary sur-
gery, we could choose not to perform axillary dissec-
tion but only radiotherapy in those patients with clini-
cally negative  axilla in order to perform adjuvant the-
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rapy not on the basis of nodal status but of biologic fac-
tors tested on the primary tumour (6, 7).
In an early future we could suggest that sentinel
node biopsy could not be associated with axillary sur-
gery, but with a close and careful follow-up in patients
with early stage breast cancer. 
Lastly, it could be also suggested lymphoscinti-
graphy-which is already used for the dectection of sen-
tinel node-as means to led biologically active therapeu-
tic radionuclides directed towards tumour receptors
(monoclonal antibodies, peptides, avidine-biotine, etc)
into the target tissue.
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